Samsung Biologics to Acquire PolyPeptide Group for $1.8 Billion in Cash
Samsung Biologics has announced a significant all-cash acquisition of PolyPeptide Group for $1.8 billion, marking a historic deal in South Korea's biopharmaceutical sector. This move aims to enhance Samsung's portfolio in the rapidly growing peptide therapeutics market, particularly in obesity treatments.